Adam B Polis
Overview
Explore the profile of Adam B Polis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
705
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Clark L, Watkins L, Pina I, Elmer M, Akinboboye O, Gorham M, et al.
Curr Probl Cardiol
. 2020 Jul;
46(3):100647.
PMID: 32723500
No abstract available.
2.
McClung M, ODonoghue M, Papapoulos S, Bone H, Langdahl B, Saag K, et al.
Lancet Diabetes Endocrinol
. 2019 Nov;
7(12):899-911.
PMID: 31676222
Background: Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bone mass....
3.
Toth P, Bays H, Brown W, Catapano A, Davidson M, Farnier M, et al.
J Clin Lipidol
. 2019 Oct;
13(6):997-1007.e8.
PMID: 31629703
Background: Elevated remnant lipoprotein cholesterol (RLP-C) levels increase cardiovascular disease risk. However, RLP-C measurement methods are not standardized, leading to variations across studies. Objective: To evaluate the effect of ezetimibe...
4.
Clark L, Watkins L, Pina I, Elmer M, Akinboboye O, Gorham M, et al.
Curr Probl Cardiol
. 2018 Dec;
44(5):148-172.
PMID: 30545650
Clinical trial results provide the critical evidence base for evaluating the safety and efficacy of new medicines and medical products. Efficacy and safety may differ among population subgroups depending on...
5.
Toth P, Catapano A, Farnier M, Foody J, Tomassini J, Jensen E, et al.
Am J Cardiol
. 2016 Oct;
118(12):1812-1820.
PMID: 27756478
Statin therapy is associated with a slightly increased risk of developing diabetes mellitus and insulin resistance in patients without diabetes. Ezetimibe combined with statins may be considered for high-risk patients...
6.
Davidson M, Tomassini J, Jensen E, Neff D, Polis A, Tershakovec A
Data Brief
. 2016 Feb;
6:530-41.
PMID: 26904712
This brief article provides complementary data supporting the results reported in "Changing Characteristics of Statin-related cIMT Trials from 1988 to 2006" [1]. That article described time-related trends in baseline factors...
7.
Davidson M, Tomassini J, Jensen E, Neff D, Polis A, Tershakovec A
Atherosclerosis
. 2016 Jan;
246:121-9.
PMID: 26773471
Objectives: Changes in cIMT have not been consistently correlated with cardiovascular risk reduction in clinical studies. The variability of carotid intima media thickness (cIMT) changes in published statin LDL-C-lowering studies...
8.
Descamps O, Tomassini J, Lin J, Polis A, Shah A, Brudi P, et al.
Atherosclerosis
. 2015 Apr;
240(2):482-9.
PMID: 25913444
Objective: We compared the variability of LDL-C-lowering responses to treatment with ezetimibe + statins versus statins in hypercholesterolemic patients. Methods: An analysis of patient-level data pooled from 27 double-blind, placebo...
9.
Ambegaonkar B, Tipping D, Polis A, Tomassini J, Tershakovec A
Atherosclerosis
. 2014 Dec;
237(2):829-37.
PMID: 25463129
Objective: Evaluate the lipid-altering effects of ezetimibe added to ongoing statin therapy, statin titration, switching from statin monotherapy to a more potent statin or to ezetimibe/simvastatin. Methods: A pooled analysis...
10.
Bays H, Chen E, Tomassini J, McPeters G, Polis A, Triscari J
Fundam Clin Pharmacol
. 2014 Nov;
29(2):209-18.
PMID: 25431239
Co-administration of ezetimibe with atorvastatin is a generally well-tolerated treatment option that reduces LDL-C levels and improves other lipids with greater efficacy than doubling the atorvastatin dose. The objective of...